U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Anaplastic Lymphoma

MedGen UID:
272106
•Concept ID:
C1321546
•
Neoplastic Process
Synonym: Anaplastic Large B-Cell Lymphoma

Definition

A diffuse large B-cell lymphoma variant characterized by the presence of large round, oval, or polygonal cells with bizarre pleomorphic nuclei resembling Hodgkin or Reed-Sternberg cells. It is unrelated to anaplastic large cell lymphoma which is a T-cell non-Hodgkin lymphoma. [from NCI]

Professional guidelines

PubMed

A pragmatic guide for management of adverse events associated with lorlatinib.
Liu G, Mazieres J, Stratmann J, Ou SI, Mok T, Grizzard M, Goto Y, Felip E, Solomon BJ, Bauer TM
Lung Cancer 2024 May;191:107535. Epub 2024 Mar 15 doi: 10.1016/j.lungcan.2024.107535. PMID: 38554546
T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.
Horwitz SM, Ansell S, Ai WZ, Barnes J, Barta SK, Brammer J, Clemens MW, Dogan A, Foss F, Ghione P, Goodman AM, Guitart J, Halwani A, Haverkos BM, Hoppe RT, Jacobsen E, Jagadeesh D, Jones A, Kallam A, Kim YH, Kumar K, Mehta-Shah N, Olsen EA, Rajguru SA, Rozati S, Said J, Shaver A, Shea L, Shinohara MM, Sokol L, Torres-Cabala C, Wilcox R, Wu P, Zain J, Dwyer M, Sundar H
J Natl Compr Canc Netw 2022 Mar;20(3):285-308. doi: 10.6004/jnccn.2022.0015. PMID: 35276674
Small cell lung cancer transformation: From pathogenesis to treatment.
Yin X, Li Y, Wang H, Jia T, Wang E, Luo Y, Wei Y, Qin Z, Ma X
Semin Cancer Biol 2022 Nov;86(Pt 2):595-606. Epub 2022 Mar 8 doi: 10.1016/j.semcancer.2022.03.006. PMID: 35276343

Recent clinical studies

Etiology

Comparative safety of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced anaplastic lymphoma kinase-mutated non-small cell lung cancer: Systematic review and network meta-analysis.
Luo Y, Zhang Z, Guo X, Tang X, Li S, Gong G, Gao S, Zhang Y, Lin S
Lung Cancer 2023 Oct;184:107319. Epub 2023 Aug 7 doi: 10.1016/j.lungcan.2023.107319. PMID: 37597303
EML4-ALK biology and drug resistance in non-small cell lung cancer: a new phase of discoveries.
Elshatlawy M, Sampson J, Clarke K, Bayliss R
Mol Oncol 2023 Jun;17(6):950-963. Epub 2023 May 15 doi: 10.1002/1878-0261.13446. PMID: 37149843Free PMC Article
Cancer of unknown primary.
Lee MS, Sanoff HK
BMJ 2020 Dec 7;371:m4050. doi: 10.1136/bmj.m4050. PMID: 33288500
Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study.
Camidge DR, Dziadziuszko R, Peters S, Mok T, Noe J, Nowicka M, Gadgeel SM, Cheema P, Pavlakis N, de Marinis F, Cho BC, Zhang L, Moro-Sibilot D, Liu T, Bordogna W, Balas B, Müller B, Shaw AT
J Thorac Oncol 2019 Jul;14(7):1233-1243. Epub 2019 Mar 20 doi: 10.1016/j.jtho.2019.03.007. PMID: 30902613
Non-small-cell lung cancer.
Gridelli C, Rossi A, Carbone DP, Guarize J, Karachaliou N, Mok T, Petrella F, Spaggiari L, Rosell R
Nat Rev Dis Primers 2015 May 21;1:15009. doi: 10.1038/nrdp.2015.9. PMID: 27188576

Diagnosis

Real-world therapeutic effectiveness of lorlatinib after alectinib in Japanese patients with ALK-positive non-small-cell lung cancer.
Goto Y, Shukuya T, Murata A, Kikkawa H, Emir B, Wiltshire R, Miura S
Cancer Sci 2023 Jun;114(6):2560-2568. Epub 2023 Apr 2 doi: 10.1111/cas.15777. PMID: 36866958Free PMC Article
Uncommon complications of breast prostheses.
Sánchez Rubio N, Lannegrand Menéndez B, Duque Muñoz M, Montes Fernández M, Ciudad Fernández MJ
Radiologia (Engl Ed) 2020 Jul-Aug;62(4):266-279. Epub 2020 Apr 6 doi: 10.1016/j.rx.2020.01.008. PMID: 32273126
Epithelioid Fibrous Histiocytoma: A Concise Review.
Felty CC, Linos K
Am J Dermatopathol 2019 Dec;41(12):879-883. doi: 10.1097/DAD.0000000000001272. PMID: 30289773
The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC).
Golding B, Luu A, Jones R, Viloria-Petit AM
Mol Cancer 2018 Feb 19;17(1):52. doi: 10.1186/s12943-018-0810-4. PMID: 29455675Free PMC Article
ALK-immunoreactive neoplasms.
Minoo P, Wang HY
Int J Clin Exp Pathol 2012;5(5):397-410. Epub 2012 May 23 PMID: 22808292Free PMC Article

Therapy

A pragmatic guide for management of adverse events associated with lorlatinib.
Liu G, Mazieres J, Stratmann J, Ou SI, Mok T, Grizzard M, Goto Y, Felip E, Solomon BJ, Bauer TM
Lung Cancer 2024 May;191:107535. Epub 2024 Mar 15 doi: 10.1016/j.lungcan.2024.107535. PMID: 38554546
Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial.
Camidge DR, Kim HR, Ahn MJ, Yang JCH, Han JY, Hochmair MJ, Lee KH, Delmonte A, Garcia Campelo MR, Kim DW, Griesinger F, Felip E, Califano R, Spira AI, Gettinger SN, Tiseo M, Lin HM, Liu Y, Vranceanu F, Niu H, Zhang P, Popat S
J Thorac Oncol 2021 Dec;16(12):2091-2108. Epub 2021 Sep 16 doi: 10.1016/j.jtho.2021.07.035. PMID: 34537440
First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.
Shaw AT, Bauer TM, de Marinis F, Felip E, Goto Y, Liu G, Mazieres J, Kim DW, Mok T, Polli A, Thurm H, Calella AM, Peltz G, Solomon BJ; CROWN Trial Investigators
N Engl J Med 2020 Nov 19;383(21):2018-2029. doi: 10.1056/NEJMoa2027187. PMID: 33207094
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study.
Mok T, Camidge DR, Gadgeel SM, Rosell R, Dziadziuszko R, Kim DW, Pérol M, Ou SI, Ahn JS, Shaw AT, Bordogna W, Smoljanović V, Hilton M, Ruf T, Noé J, Peters S
Ann Oncol 2020 Aug;31(8):1056-1064. Epub 2020 May 11 doi: 10.1016/j.annonc.2020.04.478. PMID: 32418886
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O'Brien M, Rao S, Hotta K, Leiby MA, Lubiniecki GM, Shentu Y, Rangwala R, Brahmer JR; KEYNOTE-024 Investigators
N Engl J Med 2016 Nov 10;375(19):1823-1833. Epub 2016 Oct 8 doi: 10.1056/NEJMoa1606774. PMID: 27718847

Prognosis

Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK+ ALCL: results of COG trial ANHL12P1.
Lowe EJ, Reilly AF, Lim MS, Gross TG, Saguilig L, Barkauskas DA, Wu R, Alexander S, Bollard CM
Blood 2021 Jul 1;137(26):3595-3603. doi: 10.1182/blood.2020009806. PMID: 33684925Free PMC Article
Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study.
Camidge DR, Dziadziuszko R, Peters S, Mok T, Noe J, Nowicka M, Gadgeel SM, Cheema P, Pavlakis N, de Marinis F, Cho BC, Zhang L, Moro-Sibilot D, Liu T, Bordogna W, Balas B, Müller B, Shaw AT
J Thorac Oncol 2019 Jul;14(7):1233-1243. Epub 2019 Mar 20 doi: 10.1016/j.jtho.2019.03.007. PMID: 30902613
Epithelioid Fibrous Histiocytoma: A Concise Review.
Felty CC, Linos K
Am J Dermatopathol 2019 Dec;41(12):879-883. doi: 10.1097/DAD.0000000000001272. PMID: 30289773
Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer.
Solomon BJ, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, Tang Y, Wilner KD, Blackhall F, Mok TS
J Clin Oncol 2018 Aug 1;36(22):2251-2258. Epub 2018 May 16 doi: 10.1200/JCO.2017.77.4794. PMID: 29768118
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, Ou SI, Pérol M, Dziadziuszko R, Rosell R, Zeaiter A, Mitry E, Golding S, Balas B, Noe J, Morcos PN, Mok T; ALEX Trial Investigators
N Engl J Med 2017 Aug 31;377(9):829-838. Epub 2017 Jun 6 doi: 10.1056/NEJMoa1704795. PMID: 28586279

Clinical prediction guides

Real-world therapeutic effectiveness of lorlatinib after alectinib in Japanese patients with ALK-positive non-small-cell lung cancer.
Goto Y, Shukuya T, Murata A, Kikkawa H, Emir B, Wiltshire R, Miura S
Cancer Sci 2023 Jun;114(6):2560-2568. Epub 2023 Apr 2 doi: 10.1111/cas.15777. PMID: 36866958Free PMC Article
Current Landscape of Personalized Therapy.
Horn L, Cass AS
Thorac Surg Clin 2020 May;30(2):121-125. doi: 10.1016/j.thorsurg.2020.01.011. PMID: 32327170
Epithelioid Fibrous Histiocytoma: A Concise Review.
Felty CC, Linos K
Am J Dermatopathol 2019 Dec;41(12):879-883. doi: 10.1097/DAD.0000000000001272. PMID: 30289773
Translocation-Related Sarcomas.
Nakano K, Takahashi S
Int J Mol Sci 2018 Nov 28;19(12) doi: 10.3390/ijms19123784. PMID: 30487384Free PMC Article
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.
Gainor JF, Dardaei L, Yoda S, Friboulet L, Leshchiner I, Katayama R, Dagogo-Jack I, Gadgeel S, Schultz K, Singh M, Chin E, Parks M, Lee D, DiCecca RH, Lockerman E, Huynh T, Logan J, Ritterhouse LL, Le LP, Muniappan A, Digumarthy S, Channick C, Keyes C, Getz G, Dias-Santagata D, Heist RS, Lennerz J, Sequist LV, Benes CH, Iafrate AJ, Mino-Kenudson M, Engelman JA, Shaw AT
Cancer Discov 2016 Oct;6(10):1118-1133. Epub 2016 Jul 18 doi: 10.1158/2159-8290.CD-16-0596. PMID: 27432227Free PMC Article

Recent systematic reviews

Identifying optimal ALK inhibitors in first- and second-line treatment of patients with advanced ALK-positive non-small-cell lung cancer: a systematic review and network meta-analysis.
Zhao M, Shao T, Shao H, Zhou C, Tang W
BMC Cancer 2024 Feb 8;24(1):186. doi: 10.1186/s12885-024-11916-4. PMID: 38331773Free PMC Article
Comparative safety of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced anaplastic lymphoma kinase-mutated non-small cell lung cancer: Systematic review and network meta-analysis.
Luo Y, Zhang Z, Guo X, Tang X, Li S, Gong G, Gao S, Zhang Y, Lin S
Lung Cancer 2023 Oct;184:107319. Epub 2023 Aug 7 doi: 10.1016/j.lungcan.2023.107319. PMID: 37597303
Efficacy and safety of first-line treatments for patients with advanced anaplastic lymphoma kinase mutated, non-small cell cancer: A systematic review and network meta-analysis.
Peng Y, Zhao Q, Liao Z, Ma Y, Ma D
Cancer 2023 Apr 15;129(8):1261-1275. Epub 2023 Feb 7 doi: 10.1002/cncr.34664. PMID: 36748799
Targeted therapy for advanced anaplastic lymphoma kinase (<I>ALK</I>)-rearranged non-small cell lung cancer.
Cameron LB, Hitchen N, Chandran E, Morris T, Manser R, Solomon BJ, Jordan V
Cochrane Database Syst Rev 2022 Jan 7;1(1):CD013453. doi: 10.1002/14651858.CD013453.pub2. PMID: 34994987Free PMC Article
Comparison of lorlatinib, alectinib and brigatinib in ALK inhibitor-naive/untreated ALK-positive advanced non-small-cell lung cancer: a systematic review and network meta-analysis.
Wang L, Sheng Z, Zhang J, Song J, Teng L, Liu L, Li Q, Wang B, Li B
J Chemother 2022 Apr;34(2):87-96. Epub 2021 Jun 17 doi: 10.1080/1120009X.2021.1937782. PMID: 34139965

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...